Olmesartan
CAS: 144689-24-7
Ref. 3D-IH57928
1g | 1.263,00 € | ||
2g | 2.087,00 € | ||
100mg | 195,00 € | ||
250mg | 427,00 € | ||
500mg | 743,00 € |
Información del producto
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acidOlmesa
- 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-
- 1H-Imidazole-5-carboxylicacid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
- 4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid
- Cs 088
- Olmetor
- Rnh 6270
Olmesartan medoxomil is a prodrug that is hydrolyzed to olmesartan, its active form. It is a member of the angiotensin II receptor antagonists and it is used for the treatment of hypertension and heart failure. Olmesartan medoxomil reduces the risk of cardiovascular events in patients with resistant hypertension or heart failure. The drug binds to the angiotensin II type 1 receptor, thereby blocking the binding of angiotensin II to this receptor. This prevents activation of downstream signaling pathways, including phospholipase C, protein kinase C, and mitogen-activated protein kinases. Olmesartan medoxomil also blocks the formation of new blood vessels and vascular remodeling in animal models.
Propiedades químicas
Consulta técnica sobre: 3D-IH57928 Olmesartan
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.